These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15743753)

  • 1. The use of protein tyrosine phosphatase 1B and insulin receptor immunostains to differentiate nonalcoholic from alcoholic steatohepatitis in liver biopsy specimens.
    Sanderson SO; Smyrk TC
    Am J Clin Pathol; 2005 Apr; 123(4):503-9. PubMed ID: 15743753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
    Ito S; Yukawa T; Uetake S; Yamauchi M
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients.
    Ribeiro PS; Cortez-Pinto H; Solá S; Castro RE; Ramalho RM; Baptista A; Moura MC; Camilo ME; Rodrigues CM
    Am J Gastroenterol; 2004 Sep; 99(9):1708-17. PubMed ID: 15330907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathology of nonalcoholic fatty liver disease.
    Yeh MM; Brunt EM
    Am J Clin Pathol; 2007 Nov; 128(5):837-47. PubMed ID: 17951208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-alcoholic steatohepatitis.
    Das K; Kar P
    J Assoc Physicians India; 2005 Mar; 53():195-9. PubMed ID: 15926603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease in severely obese subjects.
    Gholam PM; Flancbaum L; Machan JT; Charney DA; Kotler DP
    Am J Gastroenterol; 2007 Feb; 102(2):399-408. PubMed ID: 17311652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis.
    Shimada M; Kawahara H; Ozaki K; Fukura M; Yano H; Tsuchishima M; Tsutsumi M; Takase S
    Am J Gastroenterol; 2007 Sep; 102(9):1931-8. PubMed ID: 17511754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease.
    Palekar NA; Naus R; Larson SP; Ward J; Harrison SA
    Liver Int; 2006 Mar; 26(2):151-6. PubMed ID: 16448452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis.
    Wieckowska A; Papouchado BG; Li Z; Lopez R; Zein NN; Feldstein AE
    Am J Gastroenterol; 2008 Jun; 103(6):1372-9. PubMed ID: 18510618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis.
    Itoh S; Yougel T; Kawagoe K
    Am J Gastroenterol; 1987 Jul; 82(7):650-4. PubMed ID: 3605026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM
    Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.
    Ong JP; Elariny H; Collantes R; Younoszai A; Chandhoke V; Reines HD; Goodman Z; Younossi ZM
    Obes Surg; 2005 Mar; 15(3):310-5. PubMed ID: 15826462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FibroMAX: towards a new universal biomarker of liver disease?
    Morra R; Munteanu M; Imbert-Bismut F; Messous D; Ratziu V; Poynard T
    Expert Rev Mol Diagn; 2007 Sep; 7(5):481-90. PubMed ID: 17892356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The natural history and risk factors for progression of non-alcoholic fatty liver disease and steatohepatitis.
    Miele L; Forgione A; Hernandez AP; Gabrieli ML; Vero V; Di Rocco P; Greco AV; Gasbarrini G; Gasbarrini A; Grieco A
    Eur Rev Med Pharmacol Sci; 2005; 9(5):273-7. PubMed ID: 16231589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bile acid levels are increased in the liver of patients with steatohepatitis.
    Aranha MM; Cortez-Pinto H; Costa A; da Silva IB; Camilo ME; de Moura MC; Rodrigues CM
    Eur J Gastroenterol Hepatol; 2008 Jun; 20(6):519-25. PubMed ID: 18467911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinguishing nonalcoholic steatohepatitis from fatty liver: serum-free fatty acids, insulin resistance, and serum lipoproteins.
    Bookman ID; Pham J; Guindi M; Heathcote EJ
    Liver Int; 2006 Jun; 26(5):566-71. PubMed ID: 16762001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass.
    Boza C; Riquelme A; Ibañez L; Duarte I; Norero E; Viviani P; Soza A; Fernandez JI; Raddatz A; Guzman S; Arrese M
    Obes Surg; 2005 Sep; 15(8):1148-53. PubMed ID: 16197788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein tyrosine phosphatase regulation in fibroblasts from patients with an insulin receptor gene mutation.
    Seki N; Yagi S; Suzuki Y; Shimada F; Taira M; Makino H; Amano K; Yagui K; Saito Y; Hashimoto N
    Horm Metab Res; 2008 Dec; 40(12):833-7. PubMed ID: 18925540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.